Table 1 Demographic and clinical data on 100 patients receiving extracorporeal membrane oxygenation therapy. Data are provided as median [interquartile range] or n (%) as appropriate.
Value | |
|---|---|
Demographics | |
Age, years | 56 [45–64], range 19–83 |
Sex, male/female | 67/33 |
BMI, kg/m2 | 28 [25–32] |
ECMO details | |
VV-ECMO | 31 (31%) |
VA-ECMO | 69 (69%) |
VA-ECMO + Impella | 6 (6%) |
Change of ECMO mode, from VA to VV or combined VA/V | 7 (7%) |
ECMO indication | |
Pulmonary | 35 (35%) |
Cardiac | 26 (26%) |
ECPR | 39 (39%) |
Duration of ECMO, days | 6 [3–10], range 1–52 |
1–3 days | 36 |
4–7 days | 31 |
8–13 days | 16 |
≥ 14 days | 17 |
Reason for termination of ECMO | |
Recovery | 67 (67%) |
Mortality | 33 (33%) |
Dialysis during ECMO treatment | 58 (58%) |
Comorbidity and SOFA score | |
Charlson’s Comorbidity Index | 0 [0–1], range 0–4 |
No comorbidities | 55 (55%) |
Acute myocardial infarction | 8 (8%) |
Chronic heart failure | 13 (13%) |
Chronic pulmonary disease | 8 (8%) |
Diabetes | 17 (17%) |
SOFA score, day 1 | 13 [11–15], range 6–22 |
Antiplatelet therapy | |
Day 1, single/dual | 10 (10%)/9 (9%) |
Day 4, single/dual | 3 (5%)/9 (14%) |
Day 7, single/dual | 1 (3%)/2 (5%) |
Day 14, single/dual | 0 (0%)/0 (0%) |
Mortality | |
Mortality at ECMO weaning (of total n = 100) | 33 (33%) |
30-day mortality after successful weaning (of total n = 67) | 15 (22%) |
Alive 30 days after weaning (of total n = 100) | 52 (52%) |
VV mortality, on ECMO or within 30 days after weaning (of total n = 31) | 10 (32%) |
VA (not ECPR) mortality, on ECMO or within 30 days after weaning, (of total n = 30) | 12 (40%) |
ECPR mortality, on ECMO or within 30 days after weaning, (of total n = 39) | 26 (67%) |
